Anika Therapeutics, INC 8-K filings

Anika Therapeutics reports record Q2 revenue, significant gross margin expansion, and raises full-year guidance, driven by strong commercial and OEM channel performance.

Anika Therapeutics, Inc. has entered into a Fifth Amendment to its Credit Agreement, increasing its senior revolving line of credit to $50 million with an option to extend by another $50 million.

Anika Therapeutics reported a 13% increase in first-quarter 2026 revenue to $29.6 million, driven by strong performance in both OEM and Commercial Channels, alongside a significant improvement in gross margin to 64.2%.

Anika Therapeutics reported Q4 and full-year 2025 financial results, meeting revenue and exceeding adjusted EBITDA targets, while announcing a key executive transition.

Anika Therapeutics announced a leadership transition with Steve Griffin appointed CEO, Cheryl Blanchard becoming Executive Chair, and reaffirmed its fiscal year 2025 financial guidance.

Anika Therapeutics reported a 6% revenue decrease in Q3 2025, driven by OEM channel declines, while its Commercial Channel grew 22% and the final Hyalofast PMA module was filed with the FDA.

Anika Therapeutics announced an 8% revenue decrease in Q2 2025, driven by lower OEM channel sales, while its Hyalofast clinical trial failed to meet co-primary endpoints, leading to revised long-term guidance.

Anika Therapeutics announced its Hyalofast Phase III study missed co-primary endpoints for pain and function but showed statistically significant improvements in secondary measures, with plans to file the final PMA module in H2 2025.

Anika Therapeutics, Inc. announced that its stockholders approved an amendment to the 2017 Omnibus Incentive Plan, increasing the shares reserved for awards, and re-elected three Class II directors at its Annual Meeting held on June 20, 2025.

Anika Therapeutics' Q1 2025 results show strong commercial channel growth but a decline in OEM revenue due to pricing pressures, leading to an overall revenue decrease.

Anika Therapeutics reveals that Chief Operations Officer Anne Nunes will depart on April 25, 2025, with her responsibilities being absorbed by CFO Stephen Griffin.

Anika Therapeutics announces Q4 and full-year 2024 financial results, showcasing growth in the Commercial Channel and progress in key regulatory milestones.

Anika Therapeutics finalizes the sale of Parcus Medical to Medacta Americas Manufacturing for $4.5 million, focusing on hyaluronic acid-driven osteoarthritis pain management and regenerative solutions.

Anika Therapeutics is restructuring its business by divesting assets and focusing on its core HA technology and commercial channel, while reporting a 7% revenue decrease in Q3 2024.

Anika Therapeutics has completed the sale of its Arthrosurface business and announced plans to divest its Parcus Medical business as part of a strategic review to focus on core hyaluronic acid technology and regenerative solutions.

Anika Therapeutics announced its second quarter 2024 financial results, highlighting a revenue decrease of 5% but progress in its regenerative solutions portfolio and a new share repurchase program.

Anika Therapeutics held its 2024 Annual Meeting on July 9, 2024, where stockholders elected three directors and ratified the appointment of Deloitte & Touche LLP as the company's independent auditor.

Anika Therapeutics has entered into a cooperation agreement with Caligan Partners, resulting in the appointment of two new board members and a $40 million share repurchase program.

Anika Therapeutics has announced the appointment of Stephen Griffin as its new CFO, effective June 3, 2024, while Michael Levitz will transition out of the role but remain with the company in an advisory capacity until the end of the year.

Anika Therapeutics announced a 7% revenue increase in the first quarter of 2024, driven by strong demand and favorable order timing, and is on track to meet its 2024 profitability targets.

Anika Therapeutics exceeded expectations in Q4 and full year 2023, driven by record OA Pain Management revenue and is implementing cost reduction initiatives to improve profitability.

Anika Therapeutics announces the retirement of board member Jeffery S. Thompson and the appointment of John B. Henneman, III as the new Chair of the Board.